This potential gap of knowledge represents a not negligible obstacle for efficacious clinical management of DKD, since combination therapy with SGLT-2 inhibitors and GLP-1R agonists is currently reimbursed by the Italian Health care System when prescribed by specialists in Diabetology only. The gene discussed is SLC5A2; the disease is diabetic kidney disease.